• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Biohaven's drug for neurological disease fails late-stage study

cafead

Administrator
Staff member
  • cafead   May 23, 2022 at 10:02: AM
via Biohaven Pharmaceutical said on Monday its experimental drug for patients with spinocerebellar ataxia, a genetic disease that affects the nervous system, failed to meet the main goal of a late-stage study.

article source
 

<